Home / Business and Economy / Humana Stock Soars Past Market Benchmarks
Humana Stock Soars Past Market Benchmarks
15 Aug
Summary
- Humana stock gained 36.5% over the past year.
- Q2 adjusted EPS of $7.61 exceeded expectations of $6.22.
- Analysts consensus is a 'Moderate Buy' rating.
Humana Inc. (HUM), based in Louisville, Kentucky, has seen its stock significantly outperform the broader market over the past year. The company's shares have surged by 36.5%, substantially exceeding the S&P 500's nearly 20.6% gain and the iShares U.S. Healthcare Providers ETF's 29.1% rise.
This strong performance is attributed to improved operational efficiency and enhanced Stars ratings. Favorable cost trends, particularly among value-based care members, and savings from centralization and outsourcing have bolstered margins. Humana announced plans to exit certain 2027 Medicare Advantage plans to concentrate on higher-value products, and is leveraging proceeds from the Gentiva sale for the MaxHealth acquisition. A new Illinois Medicaid contract is also fueling growth beyond its core Medicare Advantage business.
In Q2, Humana's adjusted EPS reached $7.61, surpassing the $6.22 forecast, with adjusted revenue of $40.9 billion also exceeding expectations. For the full year, the company anticipates adjusted EPS of $9. Despite a projected 47% diluted EPS decline for the current fiscal year ending December, Humana has a strong earnings surprise history, beating estimates for the past four quarters. Currently, 26 analysts covering HUM stock recommend a 'Moderate Buy'.
